Aug 13, 2020 · In this work, we constructed CAR T cells that target PD-L1 and evaluated their efficacy in NSCLC with either high or low PD-L1 expression. PD-L1-CAR T cells exhibited antigen-specific activation, cytokine production, and cytotoxic activity against PD-L1 high NSCLC cells and xenograft tumors.

In this study we tested the hypothesis that integrating specific antibody recognition sites for PD-L1 into a CAR will endow T cells with both specificity against PD-L1-expressing leukemia cells and resistance to PD-1/PD-L1-mediated immunosuppression.

Apr 26, 2024 · Chimeric antigen receptor (CAR)-T cell therapy for solid tumors faces significant hurdles, including T-cell inhibition mediated by the PD-1/PD-L1 axis. The effects of disrupting this pathway...

Feb 26, 2021 · Unlike control T cells, aPDL1-CART cells significantly halted the expansion and reduced the viability of co-cultured leukemia cells (Raji, CD46, and K562) overexpressing PD-L1, and this effect was paralleled by increased secretion of IL-2 and IFN-γ.

Chimeric antigen receptor (CAR)-T cell therapy for solid tumors faces sig-nificant hurdles, including T-cell inhibition mediated by the PD-1/PD-L1 axis. The effects of disrupting this pathway...

In this study, we designed and prepared CAR-T cells that could secrete PD-L1 blocking antibody and target Mesothelin antigen (Sec-MesoCAR-T), to remove the immunosuppressive effect of tumor on CAR-T cells, thereby increasing the therapeutic effect of CAR-T …

Dec 19, 2024 · In this study, we developed a PD-L1 CAR T cell therapy, designated MC9999, using a humanized anti-human PD-L1 monoclonal antibody. We demonstrated the antitumor effects of MC9999 CAR T cells against various solid tumor models, including patient-derived primary tumor cell lines.

Jan 1, 2020 · Although anti-PD-1 or PD-L1 monoclonal antibodies (mAbs) are used to block the PD-1/PD-L1 regulatory axis in most clinical studies to-date, cell-intrinsic disruption of immune checkpoints by gene editing in CAR-T cells could be a better way to enhance the antitumor activity of the CAR-T cells.

Recently, combining these approaches into a strategy of PD-L1-targeted CAR has been proposed to target PD-L1 high tumors. Our study provides new information on the efficacy of such an approach against PD-L1 low targets. Methods New atezolizumab-based PD-L1-targeted CAR was generated and introduced into T, NK, or NK-92 cells.

Aug 13, 2020 · In this work, we constructed CAR T cells that target PD-L1 and evaluated their efficacy in NSCLC with either high or low PD-L1 expression. PD-L1-CAR T cells exhibited antigen-specific...